Swedish Orphan Biovitrum AB (SOBI) AI Stock Analysis

• Market Cap: kr95.21B
• Dividend Yield: N/A
• Average Volume (3M): 306.48K
• Price to Earnings (P/E): 24.1
• Beta (1Y): 0.92
• Revenue Growth: 13.38%
• EPS Growth: 80.71%
• Country: SE
• Employees: 1,895
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.55
• Shares Outstanding: 356,000,060
• 10 Day Avg. Volume: 318,563
• 30 Day Avg. Volume: 306,477
• PEG Ratio: -14.63
• Price to Book (P/B): 2.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 20.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr363.00
• Price Target Upside: 30.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 73 Outperform
• Price Target: kr327.00 ▲(17.63%Upside)

Swedish Orphan Biovitrum AB's strong financial performance is the primary driver of its score, showcasing robust profitability and efficient cash management. The technical analysis suggests mixed momentum, and valuation metrics indicate the stock is fairly priced, with no significant undervaluation. The absence of earnings call data and corporate events does not influence the score.

Swedish Orphan Biovitrum AB Business Overview & Revenue Model

Company Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

How the Company Makes Money

SOBI makes money primarily through the sale of its pharmaceutical products, targeting niche markets in the rare disease sectors of Hematology and Immunology. Its revenue model is centered around the commercialization of biologic drugs, which often have premium pricing due to their specialized nature and the high costs associated with their development. Key revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. SOBI also benefits from collaborations that enhance its research and development efforts, enabling the company to expand its product pipeline and sustain its market presence.

Swedish Orphan Biovitrum AB Financial Statement Overview

Summary

Swedish Orphan Biovitrum AB demonstrates solid financial performance with consistent revenue growth, strong profitability margins, a healthy capital structure, and robust cash flow generation. The company efficiently manages its income, balance sheet, and cash flow, reflecting effective management and operational efficiency.

Income Statement

Swedish Orphan Biovitrum AB shows strong financial performance with a consistent increase in revenue from 2020 to TTM (Trailing-Twelve-Months) with a notable revenue growth rate of 4.1% from the previous annual period. The company maintains robust profitability, with a gross profit margin of 74.9% and a net profit margin of 15.1% in TTM. EBIT and EBITDA margins are also healthy at 21.7% and 35.8% respectively, indicating efficient core operations and strong cash generation capabilities. Despite slight fluctuations, the upward trajectory in revenue and profitability margins reflects a well-managed income statement.

Balance Sheet

The balance sheet presents a stable financial position with total assets of 70.1 billion and stockholders' equity of 39 billion in TTM. The debt-to-equity ratio stands at a reasonable 0.36, indicating a balanced approach to leveraging. Return on equity remains strong at 10.1%, showcasing effective utilization of equity to generate profits. The equity ratio of 55.7% suggests a solid capital structure with substantial equity financing. While the company has managed debt effectively, maintaining this balance is crucial to mitigate potential risks associated with high leverage.

Cash Flow

The company's cash flow statement highlights efficient cash management. Operating cash flow to net income ratio is favorable at 1.93, indicating strong cash generation relative to net income. Free cash flow has shown significant growth of 21.5% from the previous year, reflecting the company's ability to generate cash after capital expenditures. However, the free cash flow to net income ratio stands at 1.35, suggesting room for improvement in converting earnings to cash. Overall, cash flows are robust, supporting the company's operational and investment activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	26.24B	26.03B	22.12B	18.79B	15.53B	15.26B
Gross Profit	19.66B	20.24B	17.13B	14.01B	12.04B	12.04B
EBITDA	9.41B	9.30B	7.23B	6.05B	5.71B	6.73B
Net Income	3.96B	3.88B	2.41B	2.64B	2.68B	3.25B
Balance Sheet
Total Assets	70.12B	75.44B	74.03B	52.50B	48.66B	48.28B
Cash, Cash Equivalents and Short-Term Investments	997.00M	1.14B	904.00M	1.36B	1.04B	404.00M
Total Debt	14.02B	16.73B	20.48B	9.10B	10.91B	14.57B
Total Liabilities	31.08B	35.15B	40.16B	25.97B	25.46B	28.08B
Stockholders Equity	39.03B	40.29B	33.87B	26.52B	23.20B	20.21B
Cash Flow
Free Cash Flow	5.33B	4.38B	-473.00M	3.19B	5.10B	1.36B
Operating Cash Flow	7.62B	7.39B	4.47B	4.67B	5.47B	5.21B
Investing Cash Flow	-2.44B	-3.09B	-21.90B	-1.48B	-367.00M	-3.96B
Financing Cash Flow	-4.63B	-4.00B	17.01B	-2.99B	-4.47B	-1.57B

Swedish Orphan Biovitrum AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 278.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Negative. The current price of 278 is below the 20-day moving average (MA) of 290.75, below the 50-day MA of 289.22, and below the 200-day MA of 306.71, indicating a bearish trend. The MACD of -5.22 indicates Positive momentum. The RSI at 40.48 is Neutral, neither overbought nor oversold. The STOCH value of 31.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SOBI.

Swedish Orphan Biovitrum AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOBI	73 Outperform	kr95.21B	24.08	10.57%	―	13.38%	80.71%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
0O5H		kr18.75B	79.66	2.43%	4.89%	―	―
MCOV.B	66 Neutral	kr36.99B	102.55		0.61%	18.16%	35.85%
ADDLF		$2.31B	80.44	5.83%	3.93%	―	―
BOEUF		$1.86B	162.24	18.01%	―	―	―
CAMRF		$3.71B	71.75	17.31%	―	―	―

Swedish Orphan Biovitrum AB Corporate Events

Sobi AGM Approves Key Resolutions and Growth Initiatives

At the Annual General Meeting held on May 8, 2025, Swedish Orphan Biovitrum AB (Sobi) shareholders approved several key resolutions. These included the adoption of financial statements, re-election of board members, and the implementation of long-term incentive programs. The AGM also authorized the board to issue new shares and convertible bonds, enhancing Sobi’s capacity for future growth and strategic initiatives.